| Title: | The antagonistic pleiotropy of insulin-like growth factor 1 |
| Journal: | Aging Cell |
| Published: | 7 Aug 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34363732/ |
| DOI: | https://doi.org/10.1111/acel.13443 |
| URL: | https://europepmc.org/articles/pmc8441393?pdf=render |
| Citations: | 30 (19 in last 2 years) as of 8 Aug 2024 |
Publication 5803
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
While insulin-like growth factor-1 (IGF-1) is a well-established modulator of aging and longevity in model organisms, its role in humans has been controversial. In this study, we used the UK Biobank (n = 440,185) to resolve previous ambiguities in the relationship between serum IGF-1 levels and clinical disease. We examined prospective associations of serum IGF-1 with mortality, dementia, vascular disease, diabetes, osteoporosis, and cancer, finding two generalized patterns: First, IGF-1 interacts with age to modify risk in a manner consistent with antagonistic pleiotropy; younger individuals with high IGF-1 are protected from disease, while older individuals with high IGF-1 are at increased risk for incident disease or death. Second, the association between IGF-1 and risk is generally U-shaped, indicating that both high and low levels of IGF-1 may be detrimental. With the exception of a more uniformly positive relationship between IGF-1 and cancer, these effects were remarkably consistent across a wide range of conditions, providing evidence for a unifying pathway that determines risk for most age-associated diseases. These data suggest that IGF-1 signaling could be harmful in older adults, who may actually benefit from the attenuation of biological growth pathways.</p>
4 Authors
- William B. Zhang
- Kenny Ye
- Nir Barzilai
- Sofiya Milman
Enabling scientific discoveries that improve human health